EUVIMEDEUVIMED entdecken
Übersichtsarbeit

MAP4K3/GLK: Structure, molecular pharmacology and drug development

Jingwen Wang, Xiaoe Yan, Haibo Li, Yudao Shen, Caihong Yun, Jianming Zhang

Bioorganic Chemistry · 2025-10 · 165 · 109043

DOI: 10.1016/j.bioorg.2025.109043 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bioorganic Chemistry, 2025-10. Verfasst von Jingwen Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China; Zhangjiang Institute for Advanced Study, Shanghai JiaoTong …. Hauptthemen laut MEDLINE: Drug Development, Protein Kinase Inhibitors, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 63 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

GLK (also known as MAP4K3), classified as a member of the MAP4K family, is a Ste20-like serine/threonine kinase. GLK plays a pivotal role in multiple cellular signaling pathways, including TCR-mediated immune responses, as well as the JNK, mTOR, and NF-κB signaling pathways. Due to its critical role in these key regulatory networks, GLK has been implicated in the pathogenesis of various diseases, including autoimmune diseases, cancer, aging, and COVID-19 infection. Consequently, GLK represents a promising molecular target for the development of novel therapeutic interventions for immunotherapy and oncotherapy. This review comprehensively summarizes the signaling pathways and human diseases regulated by GLK, focusing on GLK protein kinase structure, GLK-specific regulators, and profiling strategies for developing GLK-specific small-molecule inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug DevelopmentProtein Kinase InhibitorsProtein Serine-Threonine KinasesAnimalsHumansAutoimmune DiseasesCOVID-19NeoplasmsSARS-CoV-2Signal Transduction

Stichwörter der Autor:innen

GLKGLK inhibitorMAP4K familyProtein kinase structureSmall-molecule kinase inhibitor

Substanzen

Protein Kinase InhibitorsProtein Serine-Threonine KinasesMAP4K3 protein, human

Autor:innen und Institutionen

  • School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China; Zhangjiang Institute for Advanced Study, Shanghai JiaoTong University, Shanghai 201210, China.
  • RedCloud Bio Co., Ltd, Beijing 102206, China.
  • School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China.
  • Department of Biochemistry and Biophysics, School of Basic Medical Sciences, Peking University, Beijing 100191, China.
  • School of Pharmaceutical Sciences, Shanghai Jiao Tong University, Shanghai 200240, China; Zhangjiang Institute for Advanced Study, Shanghai JiaoTong University, Shanghai 201210, China; Institute of Translational Medicin…

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Wang, J., Yan, X., Li, H., Shen, Y., Yun, C., & Zhang, J. (2025). MAP4K3/GLK: Structure, molecular pharmacology and drug development. Bioorganic Chemistry, 165, 109043. https://doi.org/10.1016/j.bioorg.2025.109043

Vancouver

Wang J, Yan X, Li H, Shen Y, Yun C, Zhang J. MAP4K3/GLK: Structure, molecular pharmacology and drug development. Bioorganic Chemistry. 2025;165:109043. doi:10.1016/j.bioorg.2025.109043

BibTeX
@article{Wang2025,
  author = {Wang, Jingwen and Yan, Xiaoe and Li, Haibo and Shen, Yudao and Yun, Caihong and Zhang, Jianming},
  title = {MAP4K3/GLK: Structure, molecular pharmacology and drug development},
  journal = {Bioorganic Chemistry},
  year = {2025},
  volume = {165},
  pages = {109043},
  doi = {10.1016/j.bioorg.2025.109043}
}
Kostenlos starten →